Clinical implications of free-to-total immunoreactive prostate-specific antigen ratios

By Wymenga L. F. A.   Duisterwinkel F. J.   Groenier K.   Brummen P. Visser-van   Marrink J.   Mensink H. J. A.  

Scandinavian Journal of Urology and Nephrology, Vol. 34, Iss. 3, 2000-08 ,pp. : 181-187

Informa Healthcare

Access to resources Recommend Favorite

Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer

By Chen Y.-T.   Luderer A.A.   Thiel R.P.   Carlson G.   Cuny C.L.   Soriano T.F.  

Urology, Vol. 47, Iss. 4, 1996-04 ,pp. : 518-524

Elsevier

Access to resources Recommend Favorite

Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen

By Luderer A.A.   Chen Y.-T.   Soriano T.F.   Kramp W.J.   Carlson G.   Cuny C.   Sharp T.   Smith W.   Petteway J.   Brawer M.K.   Thiel R.  

Urology, Vol. 46, Iss. 2, 1995-08 ,pp. : 187-194

Elsevier

Access to resources Recommend Favorite

Free/total prostate-specific antigen ratio can prevent unnecessary prostate biopsies - September 1 and 2, 1994

By Trinkler F.B.   Schmid D.M.   Hauri D.   Pei P.   Maly F.E.   Sulser T.  

Urology, Vol. 52, Iss. 3, 1998-09 ,pp. : 479-486

Elsevier

Access to resources Recommend Favorite

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater

By Becker C.   Piironen T.   Pettersson K.   Hugosson J.   Lilja H.  

Urology, Vol. 55, Iss. 5, 2000-05 ,pp. : 694-699

Elsevier

Access to resources Recommend Favorite